NuVasive Grows Presence in Cervical and International Markets

NuVasive reported 1Q22 orthopedic sales of $290.8 million, +7.2% vs. 1Q21. Portfolio expansion and strong international performances drove company growth.

Company CFO Matt Harbaugh called the first quarter a tale of two halves, as COVID and healthcare staffing shortages severely impacted the beginning of 2022. However,  February and March...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us